Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Turkey / NCT07197359
Active, not recruiting Observational

Looksmaxxing AI for Chin Deviation Detection

NCT07197359 · tracked via the Priya Life Science Turkey tracker
Sponsor
Konya Necmettin Erbakan Üniversitesi
Phase
Observational
Started
2025-09-01
Last updated
2025-10-02

Condition(s) studied

Mandibular Asymmetry

Investigational drug(s) / intervention(s)

Looksmaxxing AI Facial Analysis

Looksmaxxing AI Facial Analysis: Participants' standardized frontal facial photographs will be analyzed using the Looksmaxxing AI application (versions 4o and 5) to determine the presence or absence of chin deviation relative to the facial midline.

Study summary

This study aims to evaluate whether an artificial intelligence application called Looksmaxxing AI will be able to correctly identify chin deviation (chin asymmetry) from standard frontal facial photographs. A total of 540 photographs will be included in the study. The eye areas will be covered to protect identity. Each photo will be analyzed by the AI, and its answers will be compared with clinical reality. The accuracy of two versions of the software (Looksmaxxing 4o and 5) will be assessed. The results may help show whether simple photo-based analysis can support early detection of chin asymmetry, especially in areas with limited access to orthodontic examination.

Eligibility

Sex
ALL
Min age
10 Years
Max age
40 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Absence of any craniofacial anomaly No major wound or scar in the facial or neck region No history of previous orthodontic treatment For male participants: absence of a long beard that could affect the appearance of the chin Availability of standardized frontal facial photographs taken in natural head position Exclusion Criteria: * Photographs in which the patient's face appears slightly angled or turned sideways Blurred or low-quality photographs with reduced clarity

Primary outcome measure(s)

  • Accuracy of Looksmaxxing AI in Detecting Chin Deviation — At study completion (October 2025)
    The proportion of correct classifications (presence or absence of chin deviation) made by the Looksmaxxing AI application compared to the clinical gold standard, expressed as a percentage.

Trial sites (1)

FacilityCityRegionStatus
Necmettin Erbakan University Konya Konya

More Konya Necmettin Erbakan Üniversitesi trials in Turkey

MARPE-Associated Changes in Sleep and Airway Recruiting
Effect of Serum Vitamin D on MARPE Treatment Response Enrolling by invitation
Evaluation of the Effect of MARPE on Speech Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07197359 on ClinicalTrials.gov ↗ ← All trials in Turkey